Chythra R Rao, Veena G Kamath, Anuradha Nadda, Swayam P Parida, Nikita Sharma, Kapil Goel, Ranjitha S Shetty, Madhur Verma, Arvind Kumar Singh, Abhisek Mishra, Swosti Kiran, Lalit Sankhe, Madhu Gupta
{"title":"IAPSM's Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India.","authors":"Chythra R Rao, Veena G Kamath, Anuradha Nadda, Swayam P Parida, Nikita Sharma, Kapil Goel, Ranjitha S Shetty, Madhur Verma, Arvind Kumar Singh, Abhisek Mishra, Swosti Kiran, Lalit Sankhe, Madhu Gupta","doi":"10.4103/ijcm.ijcm_739_24","DOIUrl":null,"url":null,"abstract":"<p><p>Pneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are available for use in India. Pneumococcal vaccination is suggested for people aged 19-64 years with immunosuppression, chronic cardiac, lung and hepatic disease, impaired splenic function, uncontrolled diabetes mellitus, current smokers, and those abusing alcohol. It is recommended that people >65 years of age are vaccinated with PPSV23. The suggested regimen is to administer PCV13 followed by PPSV23 after one year. The vaccines have minimal side effects and tolerated well. Data on vaccine effectiveness from Indian studies is limited. Hence, documenting population demographics with surveillance on serotype specific pneumococcal disease burden in adults is needed. Following this, studies on safety, immunogenicity, and cost-effectiveness of the available vaccines need to be designed and implemented. It is suggested that in the initial phase, PCV needs to be made available for high-risk population followed by vaccination roll-out for adult population of India.</p>","PeriodicalId":45040,"journal":{"name":"Indian Journal of Community Medicine","volume":"49 Suppl 2","pages":"S132-S138"},"PeriodicalIF":0.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927817/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Community Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijcm.ijcm_739_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Pneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are available for use in India. Pneumococcal vaccination is suggested for people aged 19-64 years with immunosuppression, chronic cardiac, lung and hepatic disease, impaired splenic function, uncontrolled diabetes mellitus, current smokers, and those abusing alcohol. It is recommended that people >65 years of age are vaccinated with PPSV23. The suggested regimen is to administer PCV13 followed by PPSV23 after one year. The vaccines have minimal side effects and tolerated well. Data on vaccine effectiveness from Indian studies is limited. Hence, documenting population demographics with surveillance on serotype specific pneumococcal disease burden in adults is needed. Following this, studies on safety, immunogenicity, and cost-effectiveness of the available vaccines need to be designed and implemented. It is suggested that in the initial phase, PCV needs to be made available for high-risk population followed by vaccination roll-out for adult population of India.
期刊介绍:
The Indian Journal of Community Medicine (IJCM, ISSN 0970-0218), is the official organ & the only official journal of the Indian Association of Preventive and Social Medicine (IAPSM). It is a peer-reviewed journal which is published Quarterly. The journal publishes original research articles, focusing on family health care, epidemiology, biostatistics, public health administration, health care delivery, national health problems, medical anthropology and social medicine, invited annotations and comments, invited papers on recent advances, clinical and epidemiological diagnosis and management; editorial correspondence and book reviews.